193 related articles for article (PubMed ID: 20382086)
21. Managing TB in the 21st century: existing and novel drug therapies.
Guy ES; Mallampalli A
Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
[TBL] [Abstract][Full Text] [Related]
22. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
[TBL] [Abstract][Full Text] [Related]
23. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
24. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
Yew WW
Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
[TBL] [Abstract][Full Text] [Related]
25. [Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease].
Baylan O
Mikrobiyol Bul; 2011 Jan; 45(1):181-95. PubMed ID: 21341173
[TBL] [Abstract][Full Text] [Related]
26. [Future prospects of molecular epidemiology in tuberculosis].
Matsumoto T; Iwamoto T
Kekkaku; 2009 Dec; 84(12):783-4. PubMed ID: 20077862
[TBL] [Abstract][Full Text] [Related]
27. [Reform of Japan's NTP and its technical perspectives].
Mori T
Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
Almeida Da Silva PE; Palomino JC
J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
[TBL] [Abstract][Full Text] [Related]
29. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
Sacchettini JC; Rubin EJ; Freundlich JS
Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742
[TBL] [Abstract][Full Text] [Related]
30. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
Sosnik A; Carcaboso AM; Glisoni RJ; Moretton MA; Chiappetta DA
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):547-59. PubMed ID: 19914315
[TBL] [Abstract][Full Text] [Related]
31. The significance of GlgE as a new target for tuberculosis.
Kalscheuer R; Jacobs WR
Drug News Perspect; 2010 Dec; 23(10):619-24. PubMed ID: 21180647
[TBL] [Abstract][Full Text] [Related]
32. [Active drugs against Mycobacterium tuberculosis].
Coll P
Enferm Infecc Microbiol Clin; 2009 Oct; 27(8):474-80. PubMed ID: 19766360
[TBL] [Abstract][Full Text] [Related]
33. [View of development of fluoroquinolones].
Namba K
Kekkaku; 1999 Jan; 74(1):47-52. PubMed ID: 10067055
[TBL] [Abstract][Full Text] [Related]
34. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
35. Current development and future prospects in chemotherapy of tuberculosis.
Nuermberger EL; Spigelman MK; Yew WW
Respirology; 2010 Jul; 15(5):764-78. PubMed ID: 20546189
[TBL] [Abstract][Full Text] [Related]
36. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital.
Meskel DW; Abate G; Lakew M; Goshu S; Aseffa A
Ethiop Med J; 2008 Jul; 46(3):219-25. PubMed ID: 19271385
[TBL] [Abstract][Full Text] [Related]
37. Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a situational analysis.
He GX; van den Hof S; Borgdorff MW; van der Werf MJ; Cheng SM; Hu YL; Zhang LX; Wang LX
Int J Tuberc Lung Dis; 2010 Jul; 14(7):884-9. PubMed ID: 20550773
[TBL] [Abstract][Full Text] [Related]
38. [Management of TB suspected cases of drug resistant tuberculosis requiring a second treatment].
Caminero JA
Biomedica; 2004 Jun; 24 Supp 1():212-27. PubMed ID: 15495588
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Zhang Y; Yew WW
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1320-30. PubMed ID: 19861002
[TBL] [Abstract][Full Text] [Related]
40. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
Tomioka H
Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
